Business Description
Crinetics Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US22663K1079
Description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.42 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 29.51 | |||||
| Beneish M-Score | -3.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.2 | |||||
| 3-Year EPS without NRI Growth Rate | -15.1 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | 15.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -6.34 | |||||
| Future 3-5Y Total Revenue Growth Rate | 113.02 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.07 | |||||
| 9-Day RSI | 50.47 | |||||
| 14-Day RSI | 52.13 | |||||
| 6-1 Month Momentum % | 21.56 | |||||
| 12-1 Month Momentum % | 85.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.38 | |||||
| Quick Ratio | 16.38 | |||||
| Cash Ratio | 16.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.4 | |||||
| Shareholder Yield % | -9.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -29525.22 | |||||
| Net Margin % | -26747.83 | |||||
| FCF Margin % | -19413.85 | |||||
| ROE % | -38.33 | |||||
| ROA % | -33.66 | |||||
| ROIC % | -351.41 | |||||
| ROC (Joel Greenblatt) % | -536.13 | |||||
| ROCE % | -39.49 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4119.29 | |||||
| PB Ratio | 5.6 | |||||
| Price-to-Tangible-Book | 5.6 | |||||
| EV-to-EBIT | -14.79 | |||||
| EV-to-EBITDA | -14.9 | |||||
| EV-to-Revenue | 4367.71 | |||||
| EV-to-Forward-Revenue | 695.54 | |||||
| EV-to-FCF | -22.29 | |||||
| Price-to-Net-Current-Asset-Value | 6.03 | |||||
| Price-to-Net-Cash | 6.15 | |||||
| Earnings Yield (Greenblatt) % | -6.76 | |||||
| FCF Yield % | -3.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Crinetics Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.96 | ||
| EPS (TTM) (€) | -3.419 | ||
| Beta | 0.07 | ||
| Volatility % | 28.38 | ||
| 14-Day RSI | 52.13 | ||
| 14-Day ATR (€) | 1.406022 | ||
| 20-Day SMA (€) | 53.725 | ||
| 12-1 Month Momentum % | 85.31 | ||
| 52-Week Range (€) | 28.4 - 58.5 | ||
| Shares Outstanding (Mil) | 92.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Crinetics Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crinetics Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Crinetics Pharmaceuticals Inc Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc(STU:6Z4)'s stock price today?
The current price of STU:6Z4 is €53.50. The 52 week high of STU:6Z4 is €58.50 and 52 week low is €28.40.
When is next earnings date of Crinetics Pharmaceuticals Inc(STU:6Z4)?
The next earnings date of Crinetics Pharmaceuticals Inc(STU:6Z4) is 2025-02-28 Est..
Does Crinetics Pharmaceuticals Inc(STU:6Z4) pay dividends? If so, how much?
Crinetics Pharmaceuticals Inc(STU:6Z4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers